Pharmacokinetics of L-Carnitine
- A. Evans, G. Fornasini
- Medicine, BiologyClinical Pharmacokinetics
- 2003
The renal clearance of L-carnitine increases after exogenous administration, approaching GFR after high intravenous doses, and many forms of secondary carnitine deficiency, including some drug-induced disorders, arise from impaired renal tubular re absorption.
ROLE OF MRP2 IN THE HEPATIC DISPOSITION OF MYCOPHENOLIC ACID AND ITS GLUCURONIDE METABOLITES: EFFECT OF CYCLOSPORINE
- I. Westley, Leonie R. Brogan, R. Morris, A. Evans, B. Sallustio
- Biology, MedicineDrug Metabolism And Disposition
- 1 February 2006
The data suggest that CsA may also inhibit the hepatic glucuronidation of MPA in Wistar rats, and the biliary excretion of M PAGe and MPAGa seems to depend on both Mrp2 and another unidentified canalicular transporter.
Hepatic disposition of electrophilic acyl glucuronide conjugates.
- B. Sallustio, L. Sabordo, A. Evans, R. Nation
- Biology, ChemistryCurrent drug metabolism
- 31 August 2000
Changes in membrane transporter activities, as may occur due to saturation or drug-drug interactions, can significantly affect acyl glucuronide disposition, adduct formation and the disposition of parent aglycone, thereby affecting clinical efficacy and toxicity of acylglucuronide forming drugs.
Carnitine and acylcarnitines: pharmacokinetic, pharmacological and clinical aspects.
Previous research associated with the homeostasis and pharmacokinetics of L-carnitine and its esters are examined, and potential areas of future research are highlighted, to adequately characterize metabolic status.
Carnitine and Acylcarnitines
Previous research associated with the homeostasis and pharmaco-kinetics of L-carnitine and its esters are examined, and potential areas of future research are highlighted, to adequately characterize metabolic status.
Dialysis-related carnitine disorder and levocarnitine pharmacology.
- A. Evans
- Medicine, BiologyAmerican Journal of Kidney Diseases
- 1 April 2003
Pharmacokinetics of L‐carnitine in patients with end‐stage renal disease undergoing long‐term hemodialysis
Evaluated the pharmacokinetics of intravenous L‐carnitine in patients undergoing long‐term hemodialysis to find out if it can be administered to restore plasma and tissue levels.
Accumulation of trimethylamine and trimethylamine-N-oxide in end-stage renal disease patients undergoing haemodialysis.
- Marcus A. Bain, R. Faull, G. Fornasini, R. Milne, A. Evans
- Medicine, BiologyNephrology, Dialysis and Transplantation
- 1 May 2006
TMA and TMNO accumulate between haemodialysis sessions in ESRD patients, but are efficiently removed during a single haemmodialysis session.
Deformation and nano-rheology of red blood cells: an AFM investigation.
- K. Bremmell, A. Evans, C. Prestidge
- EngineeringColloids and Surfaces B: Biointerfaces
- 1 June 2006
The Disposition of Morphine and Its Metabolites in the In‐situ Rat Isolated Perfused Liver
- A. Evans, Kathryn Shanahan
- Biology, ChemistryThe Journal of pharmacy and pharmacology
- 1 April 1995
A specific HPLC method with UV detection was used to investigate the disposition of morphine and its metabolites in the in‐situ rat isolated perfused liver preparation.
...
...